
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb has demonstrated increased confidence in its pipeline, with risk-adjusted sales projections for milvexian and iber/mezi significantly raised to $1.2 billion and $3.6 billion respectively for 2033, reflecting strong potential in the stroke prevention and multiple myeloma markets. The firm has benefitted from favorable guidance ahead of consensus estimates, which has alleviated market concerns and prompted enthusiasm around its CELMoD offerings from notable expertise in the oncology field. Additionally, a robust dividend of approximately $2.50, along with prudent cost management and a resilient Growth Portfolio, further contributes to a positive financial outlook for the company.
Bears say
Bristol-Myers Squibb faces significant potential revenue and earnings impacts due to delays in regulatory approval and product launches, which can hinder its financial growth. The company's forward EV/EBITDA multiple remains below the average of its peers, indicating a potential undervaluation relative to the sector. Additionally, ongoing risks associated with clinical trials, such as regulatory hurdles and evolving market dynamics, may threaten the firm's ability to introduce successful new products, further complicating its financial outlook.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares